6 research outputs found
Intramolecular Reactions of Benzylic Azides with Ketones:Â Competition between Schmidt and Mannich Pathways
Total Synthesis of the Strychnos Alkaloid (+)-Minfiensine: Tandem Enantioselective Intramolecular Heck−Iminium Ion Cyclization
Discovery of 1‑(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)Âpyrido[2,3‑<i>d</i>]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against <i>BRAF</i> or <i>RAS</i> Mutant Tumor Cells
The
RAS-RAF-MEK-MAPK cascade is an essential signaling pathway,
with activation typically mediated through cell surface receptors.
The kinase inhibitors vemurafenib and dabrafenib, which target oncogenic
BRAF V600E, have shown significant clinical efficacy in melanoma patients
harboring this mutation. Because of paradoxical pathway activation,
both agents were demonstrated to promote growth and metastasis of
tumor cells with <i>RAS</i> mutations in preclinical models
and are contraindicated for treatment of cancer patients with <i>BRAF</i> WT background, including patients with <i>KRAS</i> or <i>NRAS</i> mutations. In order to eliminate the issues
associated with paradoxical MAPK pathway activation and to provide
therapeutic benefit to patients with <i>RAS</i> mutant cancers,
we sought to identify a compound not only active against BRAF V600E
but also wild type BRAF and CRAF. On the basis of its superior in
vitro and in vivo profile, compound <b>13</b> was selected for
further development and is currently being
evaluated in phase I clinical studies